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ABSTRACT 
Background: Approximately 30% of patients with schizophrenia show an inadequate 
response to antipsychotics, termed treatment resistance. Neuroimaging studies may 
help elucidate the underlying neurobiological reasons that certain patients show 
inadequate treatment response, and help identify them earlier. In addition, studies 
examining the effect of clozapine on the brain may help identify which aspects of 
clozapine make it uniquely effective in treatment resistance. 
 
Method: We performed a systematic search of PubMed between January 1980 and 
April 2015 in order to identify all neuroimaging studies that had examined treatment 
resistant patients, or longitudinally studied the effects of clozapine treatment.  
 
Findings: The search identified 330 papers, of which 60 met inclusion criteria. 
Replicated differences in treatment resistant relative to responsive patients include 
reductions in gray matter and perfusion of frontotemporal regions and increases in 
white matter and basal ganglia perfusion. Clozapine treatment has been shown to lead 
to reductions in caudate nuclei volumes in three separate studies. 
 
Interpretation: The available evidence supports the possibility that some of the 
neurobiological changes observed in resistant schizophrenia lie along a continuum 
with non resistant schizophrenia; while other differences may be more categorical in 
nature. There is, however, limited replication and in order for neuroimaging findings 
to be clinically translatable, future studies need to provide clear a priori hypotheses 
and test these rigorously.  
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INTRODUCTION 
 
Schizophrenia is a severe mental illness characterised by psychotic (positive), 
negative and cognitive symptoms, and has a prevalence of about 1%.1 Antipsychotic 
medication has revolutionised the treatment of schizophrenia.2 However, 20-30% of 
patients show limited response to anti-psychotic medication.3 Due to persistent 
symptoms such patients stay longer in hospital care, and have increased treatment 
costs in comparison to patients who have responded.4 Furthermore, the prognosis is 
worse the longer their symptoms do not show improvement.5 
 
Careful studies in the late 1980s and early 1990s demonstrated that less than 5% of 
patients who had not responded to two different first-line antipsychotics showed a 
response to a further antipsychotic, with the exception of clozapine.6 This has 
subsequently been confirmed in further clinical trials and naturalistic studies.7  
 
It has thus become clear that there is a group of patients whose illness does not 
respond to first-line treatment, and this has been termed treatment resistant 
schizophrenia (TRS).8 Studies of drug occupancy at D2/3 receptors have found 
comparable levels of D2 receptor occupancy in responders and non-responders, 
indicating that a failure to obtain adequate drug levels in the brain does not explain 
non-response.9  
 
These findings raise two questions. First, what is different about the underlying 
neurobiology in these patients that means antipsychotic drugs, other than clozapine, 
have little benefit? And second, what is it about clozapine that makes it uniquely 
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effective in these patients? Answering these questions is critical to developing new 
treatments for refractory schizophrenia. A further clinical need is the early 
identification of patients with TRS to allow them to start appropriate treatment 
without delay.10 Treatment guidelines recommend that patients should receive 
clozapine if they have not responded to two adequate antipsychotic trials.11 However 
in clinical practice there is generally a long delay before patients start clozapine.12 A 
biomarker that enabled the early identification of treatment resistance, potentially at 
first presentation, could obviate the current requirement for empirical trials of 
different antipsychotics.    
 
The purpose of this paper is therefore to review the neuroimaging evidence regarding 
treatment resistant schizophrenia, and consider the implications for developing new 
treatments and biomarkers for treatment resistance. 
 
  6 
METHODS 
The search was conducted within PubMed looking for studies published between 
January 1980 to April 2015. In addition to the online database search results, 
reference lists of reviews and papers identified by the search were reviewed for 
additional studies.  
 
The following key words were used as a search strategy: 
(treatment resistant OR treatment refractory OR drug resistant) 
AND 
(schizophrenia OR psychosis) 
AND 
(magnetic resonance imaging OR MRI OR functional magnetic resonance imaging  
OR fMRI OR positron emission tomography OR PET OR magnetic resonance 
spectroscopy OR MRS  OR EEG OR electroencephalography OR 
magnetoencephalography OR MEG OR event related potential OR ERP OR voxel 
based morphometry OR VBM OR diffusor tensor imaging OR DTI OR SPECT or 
SPECT or CT) 
 
Studies were selected by two independent reviewers (EM & RM). To qualify for 
inclusion, studies must have been published in peer-reviewed journals as an original 
research paper in English language. We included all studies that recruited treatment-
resistant patients and used in vivo brain imaging modalities.  We also included 
longitudinal studies reporting neuroimaging findings pre and post clozapine treatment 
in patients with resistant schizophrenia (studies solely examining clozapine receptor 
occupancy,  were not included).  
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The data extracted from each paper were: sample size, criteria for definition of 
treatment-resistance, brain imaging modality, medication status, and diagnostic 
criteria for the schizophrenia diagnosis. Where possible effect sizes for the contrasts 
of interest were calculated, measured by Cohens’s d for differences between means.  
 
 
RESULTS 
The search with the terms outlined above as well as reference list review identified 
330 papers, of which 60 met the inclusion criteria (see Fig. 1). 14 of the studies 
defined treatment resistance according to the criteria of Kane et al.13 The remainder 
used a range of definitions, while eight studies did not specify any criteria (see Table 
1).  
 
Studies comparing treatment-resistant patients with healthy control groups 
29 studies, comprising 680 patients and 714 controls, compared treatment-resistant 
patients with healthy volunteers (see Table 2). 
 
Ten structural studies were identified. Five reported overall gray matter volumes,14–18 
and all but one17 reported significant reductions. Four studies reported specific regions 
of gray matter reduction in TRS.15,16,19,20 Over 25 separate areas of reduction were 
reported, with the left middle frontal, right precentral and right middle temporal gyri 
being most consistently implicated. Regarding white matter volumes, one study of 
haloperidol treated individuals reported overall increases in TRS,14 while a study of 
clozapine treated individuals,15 and a study where medication status was not 
  8 
specified,18 reported reductions. One study showed that resistant patients 
demonstrated enlargement in posterior sections of the corpus callosum, particularly 
the splenium.21 Complementing this finding, a diffusion tensor imaging study showed 
widespread disruptions to white matter tract integrity in TRS.22 This was especially 
apparent in the corpus callosum, and illness duration was negatively related to 
fractional anisotropy in the splenium. 
 
Five studies used functional MRI (fMRI). Three resting state studies,23–25 and a study 
using a word generation task,26 have produced findings that while not necessarily 
incompatible are hard to draw coherent conclusions from as a whole. An arterial spin 
labeling (ASL) in individuals with resistant auditory hallucinations demonstrated 
increased cerebral blood flow in a variety of areas involved in speech processing.27  
 
Seven studies used positron emission tomography (PET) or single photon emission 
computed tomography (SPECT). Six of these used radiotracers that allow the 
measurement cerebral metabolic rate (e.g. 18F-fluorodeoxyglucose (FDG)) or blood 
flow (Technetium-99m-exametazime (99mTc-HMPAO), Oxygen-15(15O), and 
technetium-99m-ethyl cysteinate diethylester (99mTc-ECD)), and all but one28 
demonstrated a degree of hypofrontality in TRS. Three studies employing 99mTc-
HMPAO SPECT demonstrated reduced perfusion of frontal areas in TRS.29–31 In one 
study,29 resistant patients also showed increased perfusion ratios in the basal ganglia 
(replicated in a second study30), while reduced perfusion of the right dorsolateral 
prefrontal cortex correlated with negative symptom severity. Another study used 
99mTc-ECD SPECT, while participants performed the Wisconsin Card Sorting test. 
Individuals with TRS were had reduced rCBF in fronto-temporal regions at rest, and a 
Mouchlianitis, E., McCutcheon, R., & Howes, O. D. (2016). Brain-imaging studies of 
treatment-resistant schizophrenia: a systematic review. The Lancet Psychiatry, 3(5), 451-463. 
 
 9 
reduced percentage increase during the task.32 A FDG PET study demonstrated 
reduced activity in cortical and subcortical regions in TRS.33 Another FDG PET study 
looking specifically at resistant hallucinations demonstrated increase metabolic 
activity in a range of language related areas.28  
 
Two studies employed magnetic resonance spectroscopy (MRS). One showed 
increased glutamate concentrations in the anterior cingulate cortex of individuals with 
TRS;34 while another showed increased glutamate+glutamine concentrations in the 
putamen.35 
 
Six studies used electroencephalography (EEG). The P300 is an event related EEG 
component that occurs when a stimulus deviates from a preceding sequence of 
standard stimuli and is thought to index information processing efficiency. Two 
studies showed significant decreases in P300 amplitude in patients compared to 
controls.14,36 Two studies used the mismatch negativity (MMN) component which  is 
believed to index the integrity of the pre-attentive sensory network. These showed 
decreased amplitudes in resistant patients.37,38 One study of thirteen patients was not 
in agreement with the above findings, both in terms of MMN and P300 components.39 
Medication status of patients was not specified raising the possibility that this could 
explain the discrepancy. 
 
 
Studies comparing treatment-resistant with treatment-responsive patient groups 
Sixteen studies compared treatment-resistant (298 patients) and treatment-responsive 
groups (264 patients) (see Table 3).  
 
  10 
Seven studies used structural MRI.14–16,19,20,40,41 All demonstrated reduced gray matter 
in frontal areas in resistant compared to responsive patients (although this was not 
significant in two studies14,40). Two studies14,15 report increased white matter volumes 
in resistant patients, but only in one14 is this significant. 
 
Two studies used fMRI. A rsMRI study demonstrated that resistant patients display 
greater functional connectivity between the dorsomedial prefrontal cortex and other 
frontotemporal areas, but reduced connectivity between the ventromedial prefrontal 
cortex and areas of the cingulate cortex.23 The ASL study described above 
demonstrated increased rCBF in the left superior temporal gyrus, right supramarginal 
gyrus and temporal polar cortex in patients with treatment resistant auditory 
hallucinations.27 
 
Three studies used PET or SPECT. In contrast to the ASL study discussed above,27 in 
a 99mTc-HMPAO SPECT study, no differences in perfusion between groups were 
reported.40 One FDG PET study used a haloperidol challenge and found that this 
caused widespread metabolic decreases in resistant but not treatment-responsive 
patients.42 Demjaha et al.43 used F-DOPA PET to show increased striatal dopamine 
synthesis capacity in responsive compared to resistant patients.  
 
A sub-sample of the Demjaha et al. study43 was investigated using 1H-MRS.34 As 
described above they found that resistant patients had significantly higher anterior 
cingulate cortex glutamate levels compared to healthy controls,34 while responsive 
patients had similar levels to controls. Goldstein et al.35 showed that compared to 
individuals who have responded to first line antipsychotics, treatment resistant 
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patients who respond to clozapine show greater concentrations of 
glutamate+glutamine in the putamen, and reduced concentrations in the dorsolateral 
prefrontal cortex.  
 
Four studies used EEG. One study found that treatment-resistant patients showed 
trend level P300 decreases compared to responsive patients.14 Another showed that 
treatment-resistant patients had a different connectivity pattern than treatment-
responders, with a higher inter-hemispheric correlation between frontal electrodes.44 
Gamma-beta correlations index a response to novel auditory stimuli.45 One study 
reported significant gamma and beta frequency increases in speech-related areas and a 
significant gamma-beta correlation in resistant but not responsive patients.46 A second 
study by the same group examined this effect in terms of dimensional complexity and 
found reduced neuronal synchronisation in the prefrontal cortex of resistant patients.47  
 
 
Longitudinal studies examining the effects of clozapine in treatment-resistant patients, 
and studies investigating predictors of clozapine response 
 
We identified 33 papers, comprising a total of 844 patients and 322 controls (see 
Table 4).   
 
Eleven studies used structural neuroimaging. Three early studies used computed 
tomography (CT) scans in an attempt to identify predictors of clozapine response.48–50 
These consistently found that responders to clozapine have smaller prefrontal sulcal 
spaces compared to poor responders. Later findings that larger prefrontal51,52 and 
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temporal52 gray matter volumes are associated with a good response to clozapine are 
in keeping with the earlier CT studies. There have been some conflicting findings,  
one MRI study showed almost diametrically opposed results in that response was 
associated with larger sulcal spaces in the anterior superior temporal lobe. 53 
However, this study included treatment intolerant as well as treatment resistant 
patients, and this difference in patient population may explain this discrepancy. 
Another study, did not find any direct significant contrasts between individuals who 
had responded well to clozapine and clozapine non-responders.15 
 
Regarding the effects of clozapine treatment a longitudinal study demonstrated that 
over the course of a year patients started on clozapine showed a 10% reduction in 
caudate nuclei volume, while those remaining on typical antipsychotics showed an 
8% increase.54 These findings were replicated by in a study showing that clozapine 
use led to caudate nuclei reductions over 2455 and 52 weeks.56 Furthermore, greater 
reductions in left caudate volume were seen in clozapine responders compared to non-
responders. The findings of widespread reduced gray and increased white matter 
volumes in TRS reported by Molina et al. were attenuated during clozapine 
treatment.14 This is in contrast to a recent study showing gray matter losses in the 
prefrontal cortex were (non significantly) greater in patients treated with clozapine 
compared to healthy volunteers, although clozapine responders had less cortical 
thinning over the left medial frontal cortex and right middle temporal cortex 
compared to clozapine non-responders during this period.17  
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Twelve PET/SPECT studies were identified. Two early FDG PET studies 
demonstrated increased metabolic rates in the basal ganglia,57,58 and reduced rates in 
the frontal cortex58 following clozapine treatment. Two 99mTc-HMPAO studies, 
however, suggested that clozapine response was predicted by pre-treatment increased 
basal ganglia and frontal cortex perfusion, and that treatment reduced perfusion.30,59 
These differences may be accounted for by the fact that at the time of scanning 
individuals in the FDG studies had been antipsychotic free for at least 14 days while 
in 99mTc-HMPAO studies individuals were taking antipsychotics, which have been 
shown to alter brain metabolism.60 A later 99mTc-HMPAO study showed that 
clozapine treatment led to increased perfusion of the frontal cortex, and that this 
predicted response; again scanning occurred in this study following one week wash 
out as opposed to during antipsychotic treatment.61 
 
Some of the discrepancies’ between study findings may be accounted for by 
differences in participant medication status. However the likelihood that some of this 
heterogeneity is more intrinsic to the question under examination is well illustrated by 
two studies. One study reported individual patient findings, and described a number of 
patients showing reductions in perfusion, and others increases, in both the basal 
ganglia and frontal cortex following clozapine treatment.62 Second, a 15O-PET study 
showed that clozapine treatment led to increases in perfusion the dorsolateral part of 
the frontal cortex but decreases in the ventrolateral part.63  
 
A FDG PET study suggested that response to clozapine is modulated by different 
alleles of the DRD1 gene that codes for D1 receptors.64 It was found that cortical 
metabolic decreases were associated with clinical improvement for patients with the 
  14 
DRD1 2,2 receptor genotype but not for patients with the heterozygous DRD1 1,2 
genotype..   
 
One study employed 1H-MRS to measure N-Acetylaspartic acid (NAA), a marker of 
neuronal integrity.61 It found lower NAA levels in the dorsolateral prefrontal cortex 
were associated with clinical improvement, while 8 weeks of clozapine increased 
NAA levels (though no correlation was found with clinical improvement). Another  
study suggested individuals on clozapine who show a good response have greater 
glutamate + glutamine levels in the putamen compared to those with a poor 
response.35 
 
Ten EEG studies were identified. One study found that clozapine normalised P300 
and slow wave components;36 while another showed clozapine partially normalised 
P300 decreases, but did not have any effect on the MMN38. These findings suggest 
that clozapine possibly affects attentive but not pre-attentive processing. Five studies 
used spectral analysis to assess effects of clozapine.65–69 Two early studies65,66 
measured coherence and showed that resistant patients display interhemispheric and 
intrahemispheric dysconnectivity over anterior brain regions that clozapine partially 
normalised. These changes in coherence were also related to improvement in negative 
symptoms. Three studies demonstrated the widespread effects of clozapine on spectral 
power, indicating both increases in fast wave and slow wave power. 67–69  
 
 
 
 
DISCUSSION  
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The Neurobiology of treatment resistance 
Two main schools of thought exist regarding the neurobiology of TRS. One, which 
can be characterised as the continuum hypothesis, posits that the same 
pathophysiological processes underlie symptoms in both responsive and resistant 
patients, but that these processes occur to a greater degree in resistant patients and so 
treatment is less effective. The other, that can be considered the categorical 
hypothesis, is that resistant schizophrenia has a fundamentally different 
pathophysiology to responsive schizophrenia, and thus current treatments are 
ineffective as they target the wrong processes.70  
 
Figure 2 summarises the findings that have support from more than a single study. 
When resistant patients are compared to healthy controls, structural studies uniformly 
show gray matter reductions relative to controls, which is consistent with findings 
seen in schizophrenia in general.71 It is important to note, however, that volume 
reductions may not be universally detrimental, with one study showing an association 
between symptom severity and larger orbitofrontal cortex voumes.72 Functional 
changes were also similar to those reported in schizophrenia in general.26,27  
 
In comparing resistant and responsive patients the most replicated finding was a 
greater reduction in gray matter in resistant patients, predominantly in frontal areas. 
One fMRI27 and one EEG study14 also suggested a continuum of pathology – with 
differences observable in the treatment responders compared to controls, but more 
marked in the resistant group.  
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In terms of neurochemistry, two PET studies are consistent in suggesting that resistant 
patients might have different dopaminergic functioning relative to responsive 
patients.42,43 One F-DOPA PET study showed raised dopamine synthesis capacity in 
schizophrenia patients in general but no evidence of increased capacity in resistant 
patients.43 A FDG PET study of the effect of a haloperidol challenge showed marked 
metabolic decreases in resistant but not responsive patients.42 This can be interpreted 
as being secondary to responsive patients having elevated presynaptic dopamine 
reserves, and thus being able to accommodate the antidopaminergic effects of 
haloperidol; while treatment-resistant patients do not, resulting in decreased 
metabolism. If resistant patients do indeed have a normally functionally dopaminergic 
system, this raises the question of what neurochemical abnormalities underlie 
treatment resistance. Glutamatergic dysfunction has been implicated in the 
development of schizophrenia, in relation to both positive and negative symptoms.73–
81 The two 1H-MRS studies were consistent in showing glutamatergic elevations in 
resistant compared to responsive patients.34,35 As elevations in glutamate have been 
associated with excitotoxicity and structural brain changes82, glutamate elevations in 
resistant patients could account for the relative gray matter reductions found in some 
studies of resistant patients. Whilst this supports the idea that glutamatergic 
dysfunction underlies resistance, it needs to be tested further. 
 
Support for both continuum and categorical hypotheses can be found outside of 
neuroimaging. Recent research has suggested a potential genetic framework on which 
categorically different schizophrenia subtypes could sit,83 and neurochemically it is 
possible that categorical differences in dopaminergic and glutamatergic function 
could account for differences in treatment response.70 Conversely other studies 
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provide support for a continuum - demonstrating that patients with greater exposure to 
both environmenta,84 and genetic85 risk factors are more likely to be treatment 
resistant. 
 
Recent studies have employed multimodal imaging techniques to more precisely 
delineate the neurobiological processes underlying psychotic disorders.86–88 An 
expansion of this approach to include both thorough phenotypic characterization, and 
measurement of environmental and genetic factors may be needed to gain a fuller 
understanding of the causative factors leading to treatment resistance. 
 
Treatment resistant patients will, by definition, have greater symptom severity but 
may also have longer illness duration, and greater cumulative antipsychotic exposure 
than responsive patients. Long term exposure to antipsychotics has been shown to 
cause both increases in basal ganglia volume89 and atrophy of cortical gray matter.90,91 
As such the brain differences observed could reflect these confounds, as opposed to 
identifying pathophysiologically different illness types.  
 
 
The effects of clozapine on brain structure and function and predictors of clozapine 
response 
Two studies showed an association between clozapine treatment and reductions in 
caudate volume, while other antipsychotics were associated with enlargement.54–56 In 
addition, reductions in caudate volume were associated with a good clinical response. 
Furthermore, two SPECT studies demonstrated response to clozapine is predicted by 
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increased pre-treatment perfusion of the basal ganglia, that decreases with successful 
treatment.30,59  
 
This suggests that clozapine’s superior efficacy may be related to its normalising 
effect on striatal structure and function, consistent with its reduced affinity for the D2 
receptor.92 Some patients seem to show an initial good response to antipsychotic 
treatment and then develop treatment resistance after a number of years of 
treatment.8,93 It has been suggested that this secondary treatment resistance is due to 
D2/3 receptor supersentivity due to receptor up-regulation or other changes. 
Antipsychotic exposure is associated with dopamine D2/3 receptor up-regulation in 
rodents94 and, whilst the degree to which this happens in humans is unclear, 
antipsychotic treatment is associated with changes in striatal volume and functional 
indices in patients.89 Clozapine has a relatively low affinity for and fast dissociation 
from the D2/3 receptor.92 Thus, putatively, these actions at the D2/3 receptor could 
allow D2/3 supersensitivity to resolve, and  underlie clozapine’s efficacy for 
individuals who have developed secondary treatment resistance following sustained 
antipsychotic treatment. Whilst this is consistent with the normalisation of the striatal 
functional and structural changes seen with clozapine, this needs testing in patients. 
Moreover this is unlikely to explain all of clozapine’s clinical efficacy, not least 
because enhanced efficacy in treatment resistance is not seen with quetiapine, which 
also shows relatively low affinity for D2/3 receptors.95  
 
Clozapine has effects on a large number of other neurotransmitter systems, including 
glutamate.96 Given the glutamatergic abnormalities that have been associated with 
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resistant schizophrenia34,35 this is a element of its pharmacology which could may 
contribute to its superior efficacy.  
 
The apparent inconsistency between the two studies that showed increased perfusion 
following clozapine treatment57,58 and the others can potentially be explained by 
differences in participants’ medication status at the time of scan. The findings of Lahti 
et al. neatly illustrate the fact that striatal perfusion increases with greater D2 
antagonism.97 Therefore if a baseline scan is performed while participants are 
receiving non-clozapine antipsychotics and are then scanned again when receiving 
clozapine a reduction in perfusion might be expected (due to a relative reduction in 
D2 antagonism). If, however, the baseline scan occurs when participants are receiving 
no antipsychotic treatment, the scan following clozapine treatment might be expected 
to show increased perfusion, due to the relative increase in D2 antagonism. 
 
In terms of predicting response, early studies suggested that individuals with the most 
marked frontal atrophy were less likely to benefit from clozapine treatment;14,48–51 but 
later studies have produced conflicting results.15,53 The findings regarding clozapine’s 
longitudinal effects on global gray matter studies are too inconsistent to draw 
conclusions from. Electrophysiological studies showed that clozapine has widespread 
effects on spectral power66–68 and connectivity65,66. It appears that a good clinical 
response to clozapine is accompanied by normalization of various EEG measures 
towards the values seen in healthy controls.36,38,98 No consistent findings, however, 
show markers predicting treatment response at baseline. 
 
Current research limitations and future directions  
  20 
Our review highlights the heterogeneity that permeates neuroimaging research into 
treatment resistance. Some of this may be inherent to the problem under examination. 
There may be many ways for an illness to be treatment resistant, but only one route to 
treatment response. In particular individuals with similar clinical presentations may 
show treatment resistance due to different pharmacokinetic and pharmacodynamic 
factors, and/or vary markedly in the underlying pathoaetiology. Some of the 
heterogeneity is, however, as a result of the methods used. The cohorts studied vary 
widely in illness duration, in previous drug treatment and  treatment at time of scan,  
in sample sizes, in imaging techniques, and in analysis methods used. A further issue 
contributing to heterogeneity is that many studies were underpowered to detect even 
moderate effect sizes (e.g. Cohen’s d=0.5). Another limitation is the variable 
definition of treatment-resistance among studies. It is important that, for research 
purposes, treatment-resistance is defined using standardised, quantifiable criteria. This 
would allow for more direct comparisons across studies, which is particularly 
important in the identification of biomarkers.  
 
Cross-sectional comparisons of treatment resistant and responsive patients can 
potentially indicate differences that may underlie treatment resistance. They cannot, 
however, determine causality. Furthermore, it is difficult to exclude certain 
confounders in cross-sectional studies, for example, the finding that higher clozapine 
doses correlate with greater gray matter loss is confounded by the association of 
higher doses with disease severity.17 In view of this, where there are differences, we 
cannot exclude that they may be secondary to other factors. We did not identify any 
studies that prospectively investigated brain structure or function from illness onset to 
the development of treatment resistance. A logical strategy is to start with cross-
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sectional studies to identify brain differences between responders and resistant 
patients but, ultimately, prospective studies from illness onset are needed to identify 
what biologically underlies treatment resistance. Furthermore, prospective studies will 
be required to evaluate whether any neurobiological markers have the potential for 
clinically relevant prediction of treatment resistance. 
 
The available imaging evidence provides some limited support for both continuum 
and categorical hypotheses. This suggests a hybrid of both hypotheses may best 
describe the neurobiology of resistant schizophrenia, with some aspects such as 
structural changes on a continuum, whilst other aspects, such as presynaptic dopamine 
function, may be categorically different. It is also apparent, that whilst there have 
been fifty-nine imaging studies of resistant schizophrenia, few have attempted to 
replicate prior findings. Well controlled, ideally prospective, studies from illness 
onset are required to definitively determine the key aspects of the neurobiology 
underlying treatment resistance and identify reliable biomarkers for treatment 
resistance. 
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Authors Year Sample Resistance criteria Modality Medication at time of scan Diagnostic Criteria 
Ahmed et al.17 2015 33 TR, 31 HC 
Failed ≥2 Aps (≥1 atypical). Prolonged positive or negative symptoms of 
≥moderate severity 
MRI – Structural Pre and post clozapine  DSM-IV-TR 
Alonso-Solis et 
al.23 
2015 19 TR-AVH, 14 R, 20 HC Daily AVH AND failed ≥2 Aps (at dose equiv ≥600mg clozapine/day) fMRI – resting state Typical/Atypical Aps DSM-IV-TR 
Anderson et al.15 2015 
15 CNR, 19 TR, 18 R, 20 
HC 
Lack of significant response despite trials (adequate dose and≥6 wk duration) of 
≥2 Aps 
MRI- structural 
Atypical Aps (including 
clozapine) 
DSM-IV-TR 
Arango et al.51 2003 45 TR 
Residual positive (≥8 BPRS psychotic) or negative symptoms (≥20 SANS) 
despite ≥2 6wk AP trials. Prospective trial fluphenazine 20mg/day – subjects 
with >30% improvement excluded. 
MRI – Structural Clozapine or Haloperidol DSM-III-R 
Bartlett et al.42 1998 7 TR, 7 R 
Unmedicated BPRS ≥ 50 or medicated BPRS ≥ 42 AND no  worsening when 
unmedicated. Prospective 4-wk AP trial for patients with no records 
FDG-PET (haloperidol 
challenge) 
Not specified DSM-III-R 
Buchsbaum et al.57 1992 12 Scz Not specified FDG-PET Pre/post clozapine/thioxene Not specified 
Cachia et al.99 2008 30 TR-AVH, 28 HC Kane et al (1988) MRI-Structural Typical /atypical Aps DSM-IV 
Chakos et al.54 1995 8 clozapine, 7 typical Aps Not specified MRI- Structural Clozapine and typical Aps Not specified 
Demjaha et al.43 2012 12 TR, 12 R, 12 HC Conley et al (2001) FDOPA-PET Non clozapine Aps DSM-IV 
Demjaha et al.34 2014 6 TR, 8 R, 10 HC Conley et al (2001) 1H-MRS Typical and atypical Aps DSM-IV 
Ergun et al.62 2010 20 TR Treatment refractory or AP intolerant 99mTc-HMPAO SPECT Pre and post clozapine DSM-IV 
Ertugrul et al.61 2009 22 TR On clozapine due to treatment resistance or intolerance to previous Aps 
99mTc-HMPAO 
SPECT/ 1H-MRS 
Typical and atypical Aps DSM-IV 
Fitzgerald et al.26 2007 3 TR, 4HC 
Persistent severe refractory hallucinations that had not responded to ≥2 
adequate courses of Aps 
fMRI (word generation 
task) 
Clozapine, amisulpride, 
sertraline, valproate, diazepam 
Not specified 
Friedman et al.50 1991 34 TR 
Failure to respond to ≥2 different class Aps (each for ≥6 weeks, ≥ 800mg CPZ 
equiv). ≥4 on BPRS positive items 
CT Scan Clozapine RDC 
Galletly et al.36 2005 15 TR, 14 HC Not specified EEG Pre and post clozapine DSM-IV 
Goldstein et al.35 2015 
11 CNR, 16 TR, 15 R, 11 
HC 
NICE (2002), RANZCP (2005) 1H-MRS 
Atypical Aps including 
clozapine 
DSM-IV 
Gross et al.67 2004 16 TR Kane et al (1988) EEG Risperidone or olanzapine SCID + chart review 
Holleran et al.22 2014 19 TR, 19 HC 
Failure to respond to ≥2 Aps (≥1 atypical), prolonged moderate/severe positive 
or negative symptoms. 
MRI- DTI Atypical Aps, antidepressants DSM-IV 
Honer et al.48  1995 
42 TR (inc 3 
Schizoaffective) 
Poor response to adequate AP dose for ≥6 months. May et al. (1988) scale. CT scan 
Antipsychotic class not 
specified 
DSM-III-R 
Hoptman et al.72 2005 49 TR Kane et al (1988) MRI-Structural 
Typical and atypical Aps 
(including clozapine) 
SCID + chart review 
Horton et al.37 2011 21 TR, 19 HC Not specified EEG Clozapine DSM-IV and SCID 
Kikuchi et al.100 2014 26 TR 
Poor tolerance or poor response despite ≥2 Aps (≥1 atypical), ≥ 4 weeks and 
≥600mg CPZ equiv. 
EEG 
Pre and post clozapine 
treatment 
Not specified 
Klirova et al28 2013 15 TR-AVH, 19HC 
Non response to both typical and atypical Aps + ≥5 episodes AVH per day in 
the last month 
FDG PET  
Aps, Antidepressants, 
anticonvulsants 
DSM-IV 
Knott et al.68 2001 17 TR, 17 HC Kane et al (1988) EEG Not specified DSM-III-R 
Knott et al.66 2002 17 TR Kane et al (1988) EEG Pre/post clozapine DSM-III-R 
Konicki et al.49 2001 TR 26 Kane et al (1988) CT scan clozapine DSM-III-R 
Kubera et al.19 2014 
10 TR-AVH, 10 nAVH, 14 
HC 
Persistent AVH despite ≥2 AP trials (adequate dose, ≥6 wks) MRI Structural Clozapine and other Aps DSM-IV 
Lacroix et al.101 1995 10 TR, 10 NR 
35% or more and a 30% or less reduction, respectively, on the Brief Psychiatric 
Rating Scale (BPRS) 
EEG Not specified DSM-IV 
Mouchlianitis, E., McCutcheon, R., & Howes, O. D. (2016). Brain-imaging studies of treatment-resistant schizophrenia: a systematic review. The Lancet 
Psychiatry, 3(5), 451-463. 
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Lahti et al.63,97  
2003, 
2004 
6 partially responsive, 10 
HV 
Not specified 15O-PET Pre/post clozapine DSM-III-R 
Lauriello et al.53 1998 21 TR Treatment intolerant or inadequate response. MRI-Structural Typical Aps DSM-III-R 
Lawrie et al.40 1995 20 TR, 20 R May et al (1988) MRI-Structural/ 
SPECT 
Not specified DSM-IV 
Lee at al.46,47 
2006, 
2008 
25 TR-AVH, 23 nAVH Persistent AVH for ≥2yrs EEG Conventional neuroleptics DSM-IV 
Maller et al.18 2012 52 TR, 182 MDD, 76 HC Not specified MRI-Structural Not specified DSM-IV 
MacCrimmon et 
al.69 
2012 64 TR Kane et al (1988) EEG 
Pre/post clozapine,  (+ other 
psychotropics) 
DSM-IV 
Milovan et al.39 2004 13TR, 13 HC Kane et al (1988) EEG Not specified DSM-IV 
Mitelman et al.41 2005 13 TR, 24 R, 27 HC Keefe et al (1987) MRI-Structural Not specified DSM-IV 
Molina et al.59 1996 24 TR Lack of adequate response to ≥2 chemically different Aps, ≥800mg CPZ equiv 99mTc-HMPAO SPECT Pre/post clozapine DSM-IV 
Molina et al.29 1997a 36 TR, 28 HC Kane et al (1988) 99mTc-HMPAO SPECT Not specified DSM-IV-R 
Molina et al.30 
1997 
b 
39 TR (includes Molina et 
al. 1996 sample), 28 HC 
Lack of response to ≥2 dissimilar Aps (≥800mg CPZ equiv), each one for ≥2 
months over last year. 
99mTc-HMPAO SPECT Pre/post clozapine DSM-IV 
Molina et al.102 2003 25 TR 
Lack of response to ≥2 different Aps for ≥6 weeks in past 12 mths, dose 
≥800mg CPZ equiv. Significant positive or disorganisation residual symptoms 
MRI-structural 
FDG PET 
Pre/post clozapine DSM-III-R 
Molina et al.33,103 
2005, 
2007 
23 TR, 17NN, 18HC 
Lack of adequate response to ≥2 Aps for ≥4 weeks in preceding 12 months, 
dose ≥800mg CPZ equiv. All had haloperidol for ≥4wks before scan 
FDG PET Pre/post clozapine DSM-IV 
Molina et al.14 2008a 30 TR, 19 R and 44 HC Kane et al (1988) MRI-structural, EEG Haloperidol prior to first MRI, 
then olanzapine or clozapine 
DSM-IV 
Molina et al.31 2008b 10 TR, 10 HC 
A poor response during the previous year to haloperidol or risperidone followed 
by lack of response to 4 week trial of risperidone 
99mTc-HMPAO SPECT Pre/post clozapine DSM-IV 
Potkin et al.58 1994 18 Scz Not specified FDG PET Pre/post clozapine Not specified 
Potkin et al.64 2003 15 TR Not specified FDG PET Not specified DSM-IV 
Quarantelli et al.16 2014 
20 (TR + CNR), 15 R, 16 
HC 
<20 % improvement AND total > 45 on BPRS AND ≥4 in ≥2 BPRS psychotic 
items AND ≥2 yrs poor functioning  despite 6-8 weeks with ≥2 Aps and good 
adherence. 
MRI –structural 
Typical and atypical Aps 
(including clozapine) 
DSM-IV-TR 
Ramos et al.44 2001 10 TR, 10 R Keefe et al (1990) and Brenner & Merlo (1995) criteria EEG Not specified DSM-IV 
Ravan et al.98 2015 47 TR, 66 HC Kane et al (1988) criteria EEG (auditory evoked) Pre/Post clozapine  DSM-IV 
Scheepers et al.55 2001a 26 TR 
 
No response (CGI≥4) to ≥1 typical AP for ≥ 4 weeks OR severe EPSEs or TD MRI-Structural Pre/post clozapine DSM-IV 
Scheepers et al.56 2001 b 28 TR 
 
No response (CGI≥4) to ≥1 typical AP for ≥ 4 weeks OR severe EPSEs or TD MRI-Structural Pre/post clozapine DSM-IV 
Sun et al.21 2009 42 TR, 42 MDD, 30 HC Kane et al (1988) criteria MRI-Structural Clozapine DSM-III-R 
Tsekou et al.104 2015 7 TR 
Bremner et al (1990) criteria AND ≥70 on PANSS, and schizophrenia diagnosis 
for≥2 years 
Sleep EEG Pre/post clozapine DSM-III-R 
Umbricht et al.38 1998 11 TR, 6 R, 13 HC Partially refractory –≥4 on any of the 4 BPRS positive symptom items EEG Clozapine and haloperidol DSM-III-R 
Vercammen et al.24 2010 27 TR-AVH, 27 HC Daily AVH, ≥2 adequate AP trials MRI-Resting state Aps and benzodiazepines DSM-IV 
Wolf et al.25,27 2011, 
2012 
10 TR-AVH, 10 R, 14 HC Kane et al (1988) MRI-Resting state Clozapine DSM-IV 
Zhao et al.32 2006 21 TR, 40 HC Andreason’s negative symptom profile SPECT 
Medication free, follow up on 
clozapine 
DSM-IV 
Zugman et al.20 2013 61 TR, 67 R, 80 HC Kane et al (1988) MRI-Structural 
Typical and atypical Aps 
(including clozapine) 
DSM-IV 
Table 1: Study characteristics 
1H-MRS – proton magnetic resonance spectroscopy; AP –antipsychotic; AVH – Auditory verbal hallucinations;  BPRS – Brief Psychiatric Rating Scale; CNR – clozapine non responder; CPZ equiv – 
Chlorpromazine equivalents; DSM – Diagnostic and Statistical Manual of Mental Disorders; EEG – electroencephalogram; HC- healthy controls; MDD – major depressive disorder; MRI – Magnetic 
  36 
Resonance Imaging; PET – Positron Emission Tomography; Individuals with schizophrenia without auditory hallucinations; R – antipsychotic responders; Scz- unspecified whether 
responder/resistant; SPECT- single-photon emission computed tomography; TR – treatment resistant; TR-AVH, treatment resistant auditory verbal hallucinations.
Mouchlianitis, E., McCutcheon, R., & Howes, O. D. (2016). Brain-imaging studies of treatment-resistant schizophrenia: 
a systematic review. The Lancet Psychiatry, 3(5), 451-463. 
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Authors Year Modality Effect of interest Effect size (d) 
Ahmed et al. 2015 Structural MRI Raw brain volumes 
 GM volume in TR 0.33 (ns) 
 WM volume in TR 0.32 (ns) 
CSF volume in TR 0.19 (ns) 
Anderson et al. 2015 Structural MRI Normalised brain volumes 
GM in TR and CNR  GM: TR – 1.23 
GM: CNR – 1.90 
 WM in TR and CNR  WM: TR – 0.63 
WM: CNR – 0.99 
 CSF volume in TR and CNR CSF: TR – 0.23 (ns) 
CSF: CNR – 0.80  
GM volume bilaterally across STG, MTG, Heschl’s gyrus, central and parietal operculum, post-
central gyrus, insula, VMPFC, ACC in CNR. 
GM volume in the right central operculum and right ITG in TR 
Cachia et al. 2008 Structural MRI   Cortical folding in TR: 
Left Frontal (middle) 0.75 
Left Temporal (superior)  0.61 
Left Sylvius (diagonal branch) 0.56 
Right temporal (superior)  0.83 
Hoptman et al.  2005 Structural MRI Larger left OFC GM volumes and bilateral OFC WM volumes were associated with greater 
aggression 
Kubera et al. 2014 Structural MRI  GM in TR in predominantly of lateral prefrontal, temporal and parietal regions. 
Maller et al. 2012 Structural MRI  Raw brain volumes 
Gray matter volume in TR 0.56 
White matter volume in TR 0.66 
CSF volume in TR 0.39 
Hippocampus (tail) in TR (normalised by ICV): 
Right tail  1.71 
Left tail  1.20 
Molina et al. 2008a Structural MRI  Normalised brain volumes 
 GM volume in TR  Frontal: 1.59 
Parietal:0.87 (ns) 
Occipital: 1.40 
Temporal: 0.75 (ns) 
 WM volume in TR Frontal: 1.00 
Parietal: 1.42 
Occipital: 1.85 
Quaranatelli et al. 2014 Structural MRI global GM (normalised volumes) in TR. GM at left post central gyrus and dorsolateral superior 
frontal gyrus; right rolandic operculum, inferior frontal gyrus, insula and amygdala; and bilateral 
precentral and middle frontal gyrus. 
Sun et al. 2009 Structural MRI   Total normalised CC volume in TR 1.9 
 CC3 volume in TR  1 
 CC4 volume in TR  1 
 CC5 volume in TR 0.4 
Zugman et al. 2013 Structural MRI GM in TR in in left: orbitofrontal, middle temporal, fusiform, caudal middle frontal, STG, lingual 
areas; and right: precentral, pars triangularis, middle temporal and lateral occipital areas. 
Holleran et al. 2014 Structural MRI – 
DTI 
 Fractional anisotropy in TR in: genu, body, and splenum of CC; Temporal ILF, SLF, external 
capsule, temporal UF, posterior LIC, left anterior LIC, fornix, cerebellar peduncles and 
corticospinal tract. 
Radial diffusivity in TR in voxels in genu, body and splenum of CC, right ILF, posterior LIC, 
external capsule. 
 
Alonso-Solis et al. 2015 rsMRI FC in TR between pIPL and occipital fusiform gyrus, ligual gyrus and L occipital pole. 
Vercammen et al. 2010 rsMRI  FC in TR-AVH between the Left TPJ and Right IFG. Severity of hallucinations correlated with 
coupling between the left TPJ and: bilateral anterior cingulate and amygdala. 
Wolf et al.  2011 rsMRI  Speech-related network: connectivity in bilateral temporal and connectivity in L. anterior 
cingulate displayed by TR 
 Attention network: connectivity in R MFG in TR 
Executive function network: connectivity in L. precuneus, R.MFG, SFG in TR 
Wolf et al. 2012 MRI – Arterial 
spin labelling 
rCBF in TR in the left IFG, the left ACC, the SMA) in a cluster including the left MTG and STG, 
the left insula, the right MTG and the right SMG, extending to the right TPC 
Fitzgerald et al. 2007 fMRI (word 
generation) 
activation in TR in medial frontal regions  and greater activation in left caudal precentral gyrus. 
 
Demjaha et al. 2012 [18F]-DOPA PET Healthy volunteers and TRS show no differences in striatal dopamine synthesis capacity 
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Table 2. Treatment resistant versus healthy control studies  
ACC – anterior cingulate cortex; CC - corpus callosum; CNR – clozapine non responder; Cr – creatinine; CSF – cerebrospinal fluid; FC- functional 
connectivity; Glx – (glutamate + glutamine); GM – Gray matter; ICV – Intracranial volume; IFG – inferior frontal gyrus; ILF –inferior longitudinal 
fasciculus; ITG – inferior temporal gyrus; LIC - limb of the internal capsule; MMN - mismatch negativity; MTG - middle temporal gyrus; ns – not 
statistically significant; OFC - orbitofrontal cortex; pIPL- posterior inferior parietal lobule; SLF – superior longitudinal fasiculus; SMA –supplementary 
motor area; SMG – supramarginal gyrus; STG –superior temporal gyrus; TPC – temporoparietal cortex; TPJ – temporoparietal junction; UF- 
uncinate fasciulus; rsMRI – resting state MRI; VMPFC – ventromedial prefrontal cortex; WM- white matter 
Klirova et al. 2013  perfusion in TR in lentiform nucleus, thalamus, postcentral gyrus, left parahippocampal gyrus 
and right superior frontal gyrus. In left acoustic-linguistic cortex  found in MTG and TPJ. 
Molina et al. 1997a 99mTc-HMPAO 
SPECT 
perfusion in TR  
Right posterior temporal  1.52 
Left ventral prefrontal  0.63 
Left dorsolateral  1.56 
perfusion for TR in right basal ganglia  -1.22 
Molina et al. 1997 b 99mTc-HMPAO 
SPECT 
Right basal ganglia perfusion in HC, in CNR and in TR. 
Thalamus and left basal ganglia perfusion similar between TR and HC, CNR however shows 
perfusion in these regions. 
TR and CNR show perfusion compared to HC in left lower prefrontal dorsolateral cortex 
TR shows perfusion in upper dorsolateral cortex compared to HC or UTC 
Molina et al. 2007 FDG-PET Clozapine treated TRS show activity in, Dorsloateral cortex, OFC, ACC, insular cortex and head 
of caudate nuclei. 
Molina et al. 2008b 99mTc-HMPAO 
SPECT 
Risperidone treated TR showed  activity in the medial prefrontal, middle cingulate and insula. 
TR showed perfusion in brainstem and hippocampus, and a small part of left posterior occipital 
and temporal region 
Zhao et al. 2004 99mTc-ECD 
SPECT 
rCBF  at rest and percentage increase during Wisconsin card sorting test in TR 
Left Frontal Lobe 1.48 
Right Frontal Lobe 1.40 
Left temporal Lobe 1.31 
Right Temporal Lobe 1.48 
 
Demjaha et al. 2014 1H-MRS TR show increased ACC glutamate concentrations compared to HC 1.45 
Goldstein et al. 2015 1H-MRS TR clozapine responders have higher Glx/Cr than HC in the putamen 
(although this does not survive multiple comparisons correction) 
3.68 
 
Gallety et al. 2005 EEG TR compared to HC (prior to clozapine) show Midline N1, P300, parietal slow wave activity 
Horton et al.  2011 EEG Frequency deviant conditions: 
MMN latencies TR 0.93 
MMN amplitude for TR 1.19 
Duration deviant conditions  
No difference in MMN latency 0.59 
MMN amplitude for TR 3.14 
Milovan et al.  2004 EEG MMN amplitude in TR 
midline electrode 0.98 
lateral electrode  0.89 
Molina et al. 2008a EEG P300 amplitude in TR 2.94 
Ravan et al. 2015 EEG Machine learning investigation of EEG responses to auditory odd ball task able to classify HC and 
TRS with 81.4% accuracy 
Umbricht et al. 1998 EEG  MMN amplitudes in TR 0.99 
Mouchlianitis, E., McCutcheon, R., & Howes, O. D. (2016). Brain-imaging studies of 
treatment-resistant schizophrenia: a systematic review. The Lancet Psychiatry, 3(5), 451-463. 
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Authors Year Modality Effect of interest Effect size 
Anderson et al. 2015 Structural MRI  global GM in TR/CNR  0.84 (TR vs R) 
 GM in TR vs R: in TG, PCG, MFG, SFG, SMG gyrus and lateral occipital cortex 
 GM CNR vs R: in right parietal operculum and left cerebellum 
TR vs CNR: no significant differences 
Kubera et al. 2014 Structural MRI GM in TR-AVH compared to nAVH across a structural network involving predominantly 
medial frontal, orbitofrontal and superior temporal regions. 
Lawrie et al.  1995 Structural MRI  Whole brain volume in TRS 0.41 (ns) 
Right temporal lobe volume in TR 0.46 (ns) 
Mitelman et al. 2005 Structural MRI GM in posterior cingulate and retrosplenial cortices in TR 
Molina et al.  2008a Structural MRI 
and EEG  
 GM at baseline in TR Frontal: 0.87 
Occipital: 0.81 
 WM at baseline in TRS Frontal: 1.13 
Parietal: 1.35 
Occipital: 1.43 
in GM longitudinally in TR compared to R Frontal: 1.95 
Parietal: 2.11 
Occipital: 1.81 
in WM longitudinally in TR compared to R Frontal: 1.18 
Parietal: 1.65 
Occipital: 1.22 
Quaranatelli et al. 2014 Structural MRI GM in TR at left PCG and SFG (dorsolateral); and bilateral middle frontal gyrus. 
Zugman et al.  2013 Structural MRI  GM in DLPFC in TR  
    
Alonso-Solis et al. 2015 MRI- Resting 
state  
FC in TR between dMPFC: and central opercular cortex, insular cortex, precentral gyrus 
and STG; and between the temporal pole: and cerebellum.  
FC in TR between vMPFC: and paracingulate cortex, ACC, and subcallosal cortex; and 
between hippocampal formation and: PCC, and precuneus complex. 
Wolf et al. 2012 MRI – Arterial 
spin labelling 
rCBF in TR-AVH compared to nAVH in the left STG and right SMG, TPC. 
     
Bartlett et al.  1998 FDG PET 
(haloperidol 
challenge) 
 Whole brain metabolic rate in TR 1.2 
Left DLPFC metabolic rate in TR 1.05 
Right DLPFC metabolic rate in TR 0.87 
 Left Temporal Cortex metabolic rate in TR 1.19 
Demjaha et al. 2012 F-DOPA PET  whole striatum dopamine synthesis capacity in TR 1.11 
 associative subdivion dopamine synthesis capacity in TR 1.31 
 limbic subdivision dopamine synthesis capacity in TR 1.04 
sensorimotor subdivision (ns)  
Lawrie et al. 
 
1995 99mTc-HMPAO 
SPECT 
No significant differences in perfusion between TR and R. 
 
Goldstein et al. 2015 1H-MRS TR shows and CNR shows  Glx/CR in DLPFC  3.99 (CNR vs R) 
Glx/Cr in TR (clozapine responders) compared to R and CNR in 
putamen. 
3.31(TR vs R) 
4.00 (TR vs CNR) 
Demjaha et al. 2014 1H-MRS anterior cingulate glutamate in TR compared to R  0.70 (ns) 
 
Lee et al.  2006 EEG Beta1 in TR 0.61 
Beta2 in TR 0.69 
gamma-beta2 and beta3 correlation in TRS but not RS in posterior and 
anterior electrodes 
range of r=0.42-
0.61 
Lee et al.  2008 EEG gamma frequency in TR at D2 (i.e. more chaotic)  in right frontal 
electrode Fp2 
0.58 
beta frequency in TR at D2 (i.e. less chaotic) in left parietal electrode 
P3 
0.7 
Molina et al. 2008a EEG TR have P300 amplitude  0.53 (ns) 
Ramos et al. 2001 EEG TR have temporal alpha2,  temporal beta1, temporal beta2,  occipital beta2 
TRS have intrahemispheric correlation in Fp2-F4  
TRS haveintrahemispheric correlation between F8-T4  
 
Table 3. Treatment resistant versus treatment responder studies  
 
ACC – anterior cingulate cortex; CNR – clozapine non responder; dMPFC – dorsomedial prefrontal cortex; MFG - Middle frontal 
gyrus; nAVH – individuals not experiencing auditory halluccinations PCC – posterior cingulate cortex. PCG – post central gyrus, RS – 
  40 
responders to non-clozapine antipsychotics. STG – superior temporal gyrus. Superior frontal gyrus. SMG – supramarginal gyrus. TG 
– temporal gyrus,TR – treatment resistant.  vMPFC – ventromedial prefrontal cortex.  
Mouchlianitis, E., McCutcheon, R., & Howes, O. D. (2016). Brain-imaging studies of treatment-
resistant schizophrenia: a systematic review. The Lancet Psychiatry, 3(5), 451-463. 
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Authors Year Modality Effect of interest Effect size 
Ahmed et al. 2015 Structural MRI  GM  over 6-12 months greater in TR treated with clozapine than HC 
Right prefrontal cortex 1.06 
Left prefrontal cortex 1.02 
Periventricular area 1.85 
cortical thickness of LMFC and RMTC in CNR compared to CR. 1.07  
Anderson et al. 2015 Structural MRI No significant structural differences between TR and CNR 
Arango et al. 2003 Structural MRI In clozapine treated patients, pretreatment right prefrontal GM vol associated with response whereas 
converse true in haloperidol treated patients. 
Chakos et al. 1995 Structural MRI Patients scanned at baseline and then again 55 wks post clozapine, showed 10% in 
caudate nuclei vol, while those remaining on typical antipsychotics showed 8%  
0.94 (change within 
clozapine group) 
Honer et al. 1995 CT scan cortical sulcal spaces in clozapine responders compared to nonresponders 
Friedman et al. 1991 CT scan ++ responders have prefrontal sulcal spaces than + responders who in turn have than non-responders 
Konicki et al. 2001 CT scan prefrontal sulcal spaces in clozapine responders compared to poor responders 3.80 
Lauriello et al.  1998 Structural MRI No correlation between change in BPRS and sulcal CSF or GM volumes in PFC and frontal cortex. sulcal 
CSF volumes in anterior superior temporal lobe were associated with clinical improvement. 
Molina et al.  2003 Structural MRI  Improvement in positive symptoms related to temporal GM vol. Improvement in negative symptoms predicted 
by DLPFC vol. Improvement in disorganised dimension predicted by intracranial and hippocampal vol. 
Molina et al. 2008a Structural MRI  TR showed longitudinal changes compared to HC over (41pprox…)28 months –  GM 
in frontal, parietal and occipital regions; and in WM in frontal, parietal and occipital 
regions 
GM Frontal: 1.24 
GM Parietal: 1.68 
GM Occipital: 1.99 
WM Frontal: 1.36 
WM Parietal: 1.53 
WM Occipital: 1.63 
Scheepers et 
al. 
2001a, 
b 
Structural MRI Clozapine use led to significant in caudate nucleus volume over 24 wks. This was 
not related to clinical response at 24 weeks but when patients followed up for 52 
weeks the change in left caudate volume was significantly greater in responders 
compared to non-responders. 
0.23 (change in 
caudate over 24wks) 
0.56 (responders vs 
non responders) 
 
Buchsbaum et 
al. 
1992 FDG-PET Clozapine and thioxene metabolic rates in the basal ganglia; these effects most marked on right side. 
 Baseline metabolic rates predicted clinical medication response, with right inferior caudate metabolic rates 
differentiating clozapine and thiothixene responders 
Ergun et al. 2010 99mTc-HMPAO 
SPECT 
After 8 wks of clozapine treatment, changes in blood flow seen in 12/20 pts, mostly in basal ganglia or frontal 
cortex. 
Ertugrul et al. 2009 99mTc-HMPAO 
SPECT 
In CR perfusion ratio of Right and Left(sup and medial) frontal:caudate with treatment.  This change not seen 
in CNR. Change in perfusion ratio correlates with improvements in cognitive testing.  
Response to clozapine predicted by baseline right frontal:thalamus perfusion. 0.56 (CR vs CNR) 
Lahti et al. 2003, 
2004 
15O-PET Clozapine  and haloperidol rCBF in the striatum. Clozapine rCBF to ACC, dorsolateral frontal cortex and 
occipital cortex more than haloperidol. Both drugs led to rCBF in the hippocampus, ventrolateral frontal 
cortex and right middle temporal cortex. 
Molina et al. 2003 Structural MRI, 
FDG-PET 
Improvement of positive symptoms predicted by temporal gray matter at baseline 
Improvement of disorganised symptoms predicted by smaller intracranial and hippocampal volume 
Improvement of negative symptoms predicted by DLPFC volume and activity 
Molina et al. 2005 FDG-PET 6 mths of Clozapine treatment leads to metabolic in DLPFC, mPFC, basal ganglia and left inferior temporal 
cortex. Leads to metabolic in occipital cortex. 
activity in basal ganglia correlates with improvemnetin negative symptoms.  activity in motor area relates 
to in disorganisation symptoms. activity in primary visual area correlates with in positive symptoms. 
 
Molina et al. 
1996, 
1997b 
99mTc-HMPAO 
SPECT 
Prior to clozapine CR showed  perfusion in thalamus, basal ganglia, left lower  and right upper DLPFC. CR 
subsequently showed  in perfusion post clozapine in L basal ganglia and bilateral thalamus. 
Post clozapine treatment responders showed perfusion decrease in thalamus, basal ganglia, and dorsolateral 
cortex. Non repsonders did not show significant changes in any perfusion values. 
Molina et al. 2008b 99mTc-HMPAO 
SPECT 
Following 1 mth of clozapine pts no longer showed activity in cingulate or insular regions although pts still 
showed perfusion in MPFC. Hyperactivity in brainstem, temporolateral and occipital areas still present.  
Potkin et al. 1994 FDG PET Clozapine responders showed greater increase in perfusion following clozapine treatment in: medial occipital 
cortex and caudate head. A decrease was found in the posterior cortex and hippocampus. 
Potkin et al. 2003 FDG PET D1 2,2 homozygotes show widespread metabolic decreases following clozapine treatment and good clinical 
response – while this is not observed for D1 1,2 heterzygotes. Interestingly, heterozygotes showed worsening 
of symptoms which was associated with metabolic decreases in the left prefrontal cortex, bilateral temporal 
and an increase in right inferior temporal cortices 
Zhao et al. 2006 99mTc-ECD 
SPECT 
Clozapine had no effect on rCBF either during resting state or during Wisconsin card sorting test, although 
behavioural performance in the task occured 
 
Etrugal et al. 2009 1H-MRS Nearly significant increase in NAA/Cr ratio in Left DLPFC after clozapine treatment. 
Goldstein et al. 2015 1H-MRS CR show greater Glx/Cr than  CNR in putamen. 4.00 
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Gallety et al. 2005 EEG Clozapine treatment was associated with normalisation of P3 and late slow waves and partial normalisation of 
N1 amplitude. 
Gross et al. 2004 EEG Clozapine treatment associated with increase in theta power in midline which correlates with clinical 
improvement 
Kikuchi et al. 2014 EEG 39% of patients treated with clozapine developed EEG abnormalities. Individuals who developed 
abnormalities were more likely to be younger and have a shorter duration of illness. 
Knott et al. 2001 EEG Clozapine treatment decreases relative alpha power and mean beta/total spectrum frequency; and increases 
absolute total and delta/theta power. 
Knott et al. 2002 EEG Clozapine treatment normalises some of the inter- and intrahemispheric coherence abnormalities present at 
baseline 
Lacroix et al. 1995 EEG Clozapine treatment led to increases in theta and alpha bands 
Low responders show a greater beta1 increase than high responders 
High responders show increased coherence between a wide variety of regions (centred on the right anterior-
medial temporal region and in the theta band) that is not observed in low responders 
MacCrimmon 
et al.  
2012 EEG Baseline EEG compared with second EEG taken on average 1.4 years after starting clozapine. Clozapine 
augments power in delta and theta bands globally (particularly in frontal areas). Beta3 power reduced. Alpha 
shows a frontal increase and posterior decrease. 
Ravan et al. 2014 EEG CR EEG become indistinguishable from HV EEG following clozapine treatment, whereas CNR remain 
markedly different. 
Tsekou et al. 2015 EEG Stage 2 sleep increased with clozapine treatment, slow wave sleep reduced and REM increased. 
Umbricht et al. 1998 EEG Clozapine partially normalise P300 decreases but does not affect MMN. 
 
Table 4: Longitudinal studies of treatment resistant patients pre- and post-
clozapine, and studies predicting clozapine response 
 
CR – clozapine responder; CNR – clozapine non responder; Cr - creatinine ; DLPFC- dorsolateral prefrontal cortex; LMFC 
– left medial frontal cortex; mPFC – medial prefrontal cortex; NAA- N-acetly aspartate; pts –patients; rCBF – regional 
cerebral blood flow; RMTC – right medial temporal cortex 
Mouchlianitis, E., McCutcheon, R., & Howes, O. D. (2016). Brain-imaging studies of treatment-resistant schizophrenia: a systematic review. The Lancet 
Psychiatry, 3(5), 451-463. 
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Reco ds identified through 
database searching 
(n=304) 
Additional records identified 
through other sources 
(n=26) 
 
Records screened 
(n=330) 
Full text articles assessed for 
eligibility 
(n=330) 
Studies included in qualitative 
synthesis 
(n=60) 
Full text articles excluded 
Did not use brain imaging (n=46) 
Not specific to treatment resistance (n=225) 
Studies comparing TRS with 
HC 
(n=29) 
Studies comparing TRS with 
medication responders 
(n= 16) 
Studies examining effect 
of clozapine in TRS 
(n=33) 
Structural MRI 
(n=10) 
Ahmed, Anderson, 
Cachia, Holleran,  
Kubera, Maller, 
Molina 2008a, 
Quarantelli, Sun, 
Zugman 
 fMRI (n=5)  
Alonso-Solis, 
Fitzgerald, 
Vercammen, Wolf 
2011, 2012 
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